In August, 2008, Bergers and Hanahan reviewed all of the recent research addressing resistance to angiogenesis inhibitor therapy in the journal “Nature Reviews Cancer.” The scientists tested the ...

Angiogenesis inhibitors—a widely used class of cancer drugs designed ... and you don’t want cells around that are in attack mode.” During anti-angiogenic therapy, said Bergers, the Neill H. and Linda ...

These include: Differentiating between direct and indirect angiogenesis inhibitors. Realizing that the microvascular endothelial cell is a genetically stable target of anti-angiogenic therapy.

"Unfortunately, these anti-VEGF agents did not slow the tumor ... patients are most likely to benefit from treatment with angiogenesis inhibitors and to identify the mechanisms by which ...

Angiogenesis inhibitors can be divided in 2 main groups ... Preclinical studies of other inhibitors, including an anti-VEGFR-2 (Flk-1/KDR) monoclonal antibody, a soluble VEGFR-1 decoy (VEGFR ...

D. Anderson have found that using an anti-angiogenesis inhibitor may initially increase blood flow to a tumor rather than decrease it. "Ironically, it may reduce leakiness in blood vessels ...

7 Several angiogenesis inhibitors, also known as anti-angiogenics, have been developed and approved by regulatory authorities such as the U.S. Food and Drug Administration (FDA) to treat cancer. These ...

Angiogenesis inhibitors are a type of targeted therapy. They work by limiting the supply of blood that a tumor needs to grow and thrive. This article reviews how angiogenesis inhibitors work ...

A tumor's resistance to angiogenesis inhibitors differs from resistance to chemotherapy drugs, Bergers explains. The targets of anti-angiogenic therapy are normal cells that form the tubes of ...

"Unfortunately, these anti-VEGF agents did not slow the tumor ... patients are most likely to benefit from treatment with angiogenesis inhibitors and to identify the mechanisms by which ...